Nörodejeneratif Hastalıkların Önlenmesi ve Yönetiminde Psikobiyotiklerin Rolü
Özet
Nörodejeneratif hastalıklar, ilerleyici nöron kaybıyla seyreden ve Alzheimer hastalığı, Parkinson hastalığı ile majör depresif bozukluk gibi ciddi klinik tablolara yol açan hastalık grubudur. Bu hastalıkların patofizyolojisinde bağırsak mikrobiyotası ile merkezi sinir sistemi arasındaki çift yönlü iletişim ağı olan mikrobiyota-bağırsak-beyin ekseninin kritik bir rol oynadığı giderek daha fazla kabul görmektedir. Psikobiyotikler; bağırsak bakterileriyle etkileşim yoluyla sinir sistemi üzerinde olumlu etkiler gösteren, hem probiyotik hem de prebiyotik bileşenler içeren canlı mikroorganizmalardır. Bu bölümde psikobiyotiklerin nörodejeneratif hastalıkların önlenmesi ve yönetimindeki rolü kapsamlı biçimde ele alınmaktadır. Psikobiyotiklerin etki mekanizmaları incelendiğinde; vagus siniri aracılı sinirsel iletim, nöroinflamasyon ve oksidatif stresin baskılanması ile kısa zincirli yağ asitleri başta olmak üzere mikrobiyal metabolitlerin nöroprotektif etkileri ön plana çıkmaktadır. Alzheimer hastalığında psikobiyotik uygulamalarının amiloid plak oluşumunu ve tau hiperfosforilasyonunu azaltarak bilişsel işlevleri iyileştirdiği; Parkinson hastalığında ise dopaminerjik nöron kaybını yavaşlattığı ve motor skorları olumlu yönde etkilediği bildirilmektedir. Depresyonda ise Lactobacillus helveticus ve Bifidobacterium longum gibi belirli suşların anksiyete ve depresif belirtileri azalttığı, BDNF düzeylerini artırdığı gösterilmiştir. Mevcut bulgular umut verici olmakla birlikte, psikobiyotiklerin klinik uygulamaya taşınabilmesi için suş özgüllüğü, standart dozaj protokolleri ve uzun vadeli güvenlilik profili gibi konuların geniş ölçekli randomize kontrollü çalışmalarla netleştirilmesi gerekmektedir.
Anahtar Kelimeler: Beyin-Bağırsak Aksı, Mikrobiyota, Nörodejeneratif Hastalıklar, Probiyotikler, Psikobiyotikler
Konu Alanı: Tarım Bilimleri -> Tarım (diğer) -> Gıda Bilimi ve Gıda Teknolojisi
Abdel-Haq, R., Schlachetzki, J.C.M., Glass, C.K., & Mazmanian, S.K. (2019). Microbiome-microglia connections via the gut-brain axis. J Exp Med, 216(1), 41–59.
Agirman, G., Yu, K.B., & Hsiao, E.Y. (2021). Signaling inflammation in the gut-brain axis. Science, 374(6571), 1087–1092.
Bhat, S., Acharya, U. R., Hagiwara, Y., Dadmehr, N., & Adeli, H. (2018). Parkinson's disease: Cause factors, measurable indicators, and early diagnosis. Computers in biology and medicine, 102, 234-241.
Blaak, E.E., Canfora, E.E., Theis, S., et al. (2020). Short-chain fatty acids in human gut and metabolic health. Benef Microbes, 11, 411–455.
Bodke, H., & Jogdand, S. (2022). Role of Probiotics in Human Health. Cureus, 14, e31313.
Bottaccioli, A.G., Bologna, M., & Bottaccioli, F. (2025). Rethinking Depression - Beyond Neurotransmitters. Int J Mol Sci, 26, 2759.
Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., et al. (2014). The gut microbiota influences blood-brain barrier permeability in mice. Science Translational Medicine, 6(263), 263ra158.
Breijyeh, Z., & Karaman, R. (2020). Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules, 25(24), 5789.
Caspani, G., & Swann, J. (2019). Small talk: Microbial metabolites involved in gut-to-brain signaling. Curr Opin Pharmacol, 48, 99–106.
Castelli, V., d'Angelo, M., Quintiliani, M., Benedetti, E., Cifone, M.G., & Cimini, A. (2021). The emerging role of probiotics in neurodegenerative diseases: A new hope for Parkinson's disease? Neural Regen Res, 16, 628–634.
Chambilo, B., Dhiver, T., Sahu, K., & Parashar, R. (2025). Modulation of Gut Microbiota with Probiotics: Potential Therapeutic Pathways for Alzheimer's and Parkinson's Diseases. Journal of Neurological Sciences and Neurophysiology, 42(3), 75–83.
Chand, S.P., & Arif, H. (2023). Depression. StatPearls [Internet]. StatPearls Publishing: Treasure Island, FL, USA.
Chen, C., Wang, G.Q., Li, D.D., & Zhang, F. (2025). Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Mol Biomed, 6(1), 64.
Chen, W.L., Deng, F.S., & Tsai, Y.C. (2025). Lactiplantibacillus plantarum as a psychobiotic strategy targeting Parkinson's Disease: A review and mechanistic insights. Nutrients, 17(19), 3047.
Daneman, R., & Prat, A. (2015). The blood-brain barrier. Cold Spring Harb Perspect Biol, 7, a020412.
DaRocha-Souto, B., Coma, M., Pérez-Nievas, B. G., Scotton, T. C., Siao, M., Sánchez-Ferrer, P., ... & Gómez-Isla, T. (2012). Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease. Neurobiology of disease, 45(1), 425-437.
Di Chiano, M., Sallustio, F., Fiocco, D., Rocchetti, M.T., Spano, G., Pontrelli, P., ... & Gallone, A. (2024). Psychobiotic properties of Lactiplantibacillus plantarum in neurodegenerative diseases. International Journal of Molecular Sciences, 25(17), 9489.
Dinan, T.G., & Cryan, J.F. (2017). The microbiome-gut-brain axis in health and disease. Gastroenterology Clinics of North America, 46(1), 77–89.
Dinan, T.G., Stanton, C., & Cryan, J.F. (2013). Psychobiotics: A Novel Class of Psychotropic. Biological Psychiatry, 74, 720–726.
Disu, T. R., Anne, N. J., Griffiths, M. D., & Mamun, M. A. (2019). Risk factors of geriatric depression among elderly Bangladeshi people: a pilot interview study. Asian journal of psychiatry, 44, 163-169.
Dong, L., Li, J., Zhang, C., & Liu, D. (2021). Gut microbiota: A novel player in the pathogenesis of perioperative neurocognitive disorder? Ibrain, 7, 37–43.
World Health Organization (WHO). (2025). Mental Health and Neurological Disorders. https://www.who.int/news-room/fact-sheets/detail/mental-health-strengthening-our-response (accessed: January 8, 2025).
Foster, J.A., & McVey Neufeld, K.A. (2013). Gut-brain axis: How the microbiome influences anxiety and depression. Trends Neurosci, 36(5), 305–312.
Furness, J.B. (2012). The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol, 9(5), 286–294.
Garcez, M.L., Jacobs, K.R., & Guillemin, G.J. (2019). Microbiota alterations in Alzheimer's disease: Involvement of the kynurenine pathway and inflammation. Neurotox Res, 36, 424–436.
Garzone, S., Charitos, I.A., Mandorino, M., Maggiore, M.E., Capozzi, L., Cakani, B., ... & Colella, M. (2025). Can We Modulate Our Second Brain and Its Metabolites to Change Our Mood? A Systematic Review on Efficacy, Mechanisms, and Future Directions of "Psychobiotics". International Journal of Molecular Sciences, 26(5), 1972.
Góralczyk-Bińkowska, A., Szmajda-Krygier, D., & Kozłowska, E. (2022). The microbiota–gut–brain axis in psychiatric disorders. International Journal of Molecular Sciences, 23(19), 11245.
Guzzetta, K.E., Cryan, J.F., & O'Leary, O.F. (2022). Regulation of Adult Hippocampal Neurogenesis by the Microbiota-Gut-Brain Axis. Brain Plasticity, 8, 97–119.
Heidarzadeh-Rad, N., Gokmen-Ozel, H., Kazemi, A., Almasi, N., & Djafarian, K. (2020). Effects of Psychobiotic Supplementation on Serum Brain-Derived Neurotrophic Factor Levels in Depressive Patients. J Neurogastroenterol Motil, 26, 486–495.
Henry, T.R. (2002). Therapeutic mechanisms of vagus nerve stimulation. Neurology, 59(6_suppl_4), S3–S14.
Hossain, M.N., Lee, J., Choi, H., Kwak, Y.S., & Kim, J. (2024). Effects of exercise on depression. Phys Act Nutr, 28, 43–51.
Huang, H. J., Chen, J. L., Liao, J. F., Chen, Y. H., Chieu, M. W., Ke, Y. Y., ... & Hsieh-Li, H. M. (2021). Lactobacillus plantarum PS128 prevents cognitive dysfunction in Alzheimer’s disease mice by modulating propionic acid levels, glycogen synthase kinase 3 beta activity, and gliosis. BMC complementary medicine and therapies, 21(1), 259.
Järbrink-Sehgal, E., & Andreasson, A. (2020). The gut microbiota and mental health in adults. Current Opinion in Neurobiology, 62, 102–114.
Jiménez-Pareyón, G.R., Cristóbal-Luna, J.M., García-Martínez, Y., Garfias-Noguez, C., Ramírez-Damián, M., Torres-Maravilla, E., & Sánchez-Pardo, M.E. (2025). Psychobiotics at the Frontiers of Neurodegenerative and Neuropsychiatric Research. Microorganisms, 13(12), 2718.
Jing, Y., Yu, Y., Bai, F., Wang, L., Yang, D., Zhang, C., et al. (2021). Effect of fecal microbiota transplantation on neurological restoration in a spinal cord injury mouse model. Microbiome, 9, 1–21.
Kasarello, K., Cudnoch-Jedrzejewska, A., & Czarzasta, K. (2023). Gut Microbiota and Brain Communication via Immune and Neuroendocrine Signaling. Front Microbiol, 14, 1118529.
Kearns, R. (2024). The Gut-Brain Axis and Neuroinflammation. Cell Mol Neurobiol, 44, 64.
Krautkramer, K.A., Fan, J., & Bäckhed, F. (2021). Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol, 19, 77–94.
Kumar, A., Singh, A., & Ekavali. (2015). A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep, 67, 195–203.
Lee, S.H., Ahmad, S.R., Lim, Y.C., & Zulkipli, I.N. (2022). Use of probiotic therapy in metabolic and neurological diseases. Front Nutr, 9, 887019.
Ling, Z., Zhu, M., Yan, X., Cheng, Y., Shao, L., Liu, X., ... & Wu, S. (2021). Structural and functional dysbiosis of fecal microbiota in Chinese patients with Alzheimer's disease. Frontiers in Cell and Developmental Biology, 8, 634069.
Liu, B., Fang, F., Pedersen, N.L., Tillander, A., Ludvigsson, J.F., Ekbom, A., et al. (2017). Vagotomy and Parkinson's disease: A Swedish register-based matched-cohort study. Neurology, 88(21), 1996–2002.
Loh, J.S., Mak, W.Q., Tan, L.K.S., Ng, C.X., Chan, H.H., Yeow, S.H., et al. (2024). Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduction and Targeted Therapy, 9(1), 37.
Lu, C. S., Chang, H. C., Weng, Y. H., Chen, C. C., Kuo, Y. S., & Tsai, Y. C. (2021). The add-on effect of Lactobacillus plantarum PS128 in patients with Parkinson's disease: a pilot study. Frontiers in nutrition, 8, 650053.
Lukic, I., Ivkovic, S., Mitic, M., & Adzic, M. (2022). Tryptophan metabolites in depression: Modulation by gut microbiota. Frontiers in Behavioral Neuroscience, 16, 987697.
Madison, A.A., & Bailey, M.T. (2024). Stressed to the core: Inflammation and gut permeability link stress-associated gut microbiota shifts to mental health outcomes. Biol Psychiatry, 95(4), 339–347.
Margolis, K.G., Cryan, J.F., & Mayer, E.A. (2021). The microbiota-gut-brain axis: from motility to mood. Gastroenterology, 160(5), 1486–1501.
Mayneris-Perxachs, J., Castells-Nobau, A., Arnoriaga-Rodriguez, M., Martin, M., de la Vega-Correa, L., Zapata, C., et al. (2022). Microbiota alterations in proline metabolism affect depression. Cell Metabolism, 34, 681–701.
Megur, A., & Kumar, B. (2026). Psychobiotics and the Microbiota–Gut–Brain Axis: Bridging Functional Foods with Therapeutic Potential in Neurodegenerative and Psychiatric Disorders. Food Reviews International, 1–35.
Messaoudi, M., Violle, N., Bisson, J.F., Desor, D., Javelot, H., & Rougeot, C. (2011). Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbiomes, 2, 256–261.
Mohajeri, M.H., la Fata, G., Steinert, R.E., & Weber, P. (2018). Relationship between the gut microbiome and brain function. Nutr Rev, 76, 481–496.
Morrison, D.J., & Preston, T. (2016). Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbiomes, 7, 189–200.
Moustafa, S.A., Mohamed, S., Dawood, A., Azar, J., Elmorsy, E., Rizk, N.A., et al. (2021). The gut-brain axis: A review on the role of the microbiota in Parkinson's disease. Metab Brain Dis, 36, 1545–1557.
Ng, Q.X., Lim, Y.L., Yaow, C.Y.L., Ng, W.K., Thumboo, J., & Liew, T.M. (2023). Effect of Probiotic Supplementation on Gut Microbiota in Patients with Major Depressive Disorders: A Systematic Review. Nutrients, 15, 1351.
Nilashi, M., & Abumalloh, R.A. (2023). Parkinson's Disease Facts and Figures. Journal of Soft Computing and Decision Support Systems, 10(5), 1–6.
Omotosho, A.O., Tajudeen, Y.A., Oladipo, H.J., Yusuff, S.I., AbdulKadir, M., Muili, A.O., ... & El-Sherbini, M.S. (2023). Parkinson's disease: Are gut microbes involved? Brain and Behavior, 13(8), e3130.
Onaran, B., & Türkmen, N. (2022). Psikobiyotikler: depresyon ve anksiyete ile ilişkisi. Sağlık Bilimleri Dergisi, 31(1), 101-106.
Oroojzadeh, P., Bostanabad, S.Y., & Lotfi, H. (2022). Psychobiotics: The Influence of Gut Microbiota on the Gut-Brain Axis in Neurological Disorders. J Mol Neurosci, 72, 1952–1964.
Post, B., Van Den Heuvel, L., Van Prooije, T., Van Ruissen, X., Van De Warrenburg, B., & Nonnekes, J. (2020). Young onset Parkinson’s disease: a modern and tailored approach. Journal of Parkinson’s disease, 10(s1), S29-S36.
Prescott, S.L., & Liberles, S.D. (2022). Internal senses of the vagus nerve. Neuron, 110(4), 579–599.
Rao, Y.L., Ganaraja, B., Murlimanju, B.V., Joy, T., Krishnamurthy, A., & Agrawal, A. (2022). Hippocampus and its involvement in Alzheimer's disease: a review. 3 Biotech, 12(2), 55.
Ross, K. (2023). Psychobiotics: Are they the future intervention for managing depression and anxiety? A literature review. Explore, 19(5), 669-680.
Russo, C., Valle, M.S., Russo, A., & Malaguarnera, L. (2022). Interaction between ghrelin and microglia in neuroinflammation. Int J Mol Sci, 23, 13432.
Sharma, R., Gupta, D., Mehrotra, R., & Mago, P. (2021). Psychobiotics: The Next-Generation Probiotics for the Brain. Curr Microbiol, 78(2), 449–463.
Silva, Y.P., Bernardi, A., & Frozza, R.L. (2020). The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne), 11, 25.
Singh, N., Pillay, V., & Choonara, Y. E. (2007). Advances in the treatment of Parkinson's disease. Progress in neurobiology, 81(1), 29-44.
Sorboni, S.G., Moghaddam, H.S., Jafarzadeh-Esfehani, R., & Soleimanpour, S. (2022). A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders. Clin Microbiol Rev, 35, e0033820.
Srivastav, S., Neupane, S., Bhurtel, S., Katila, N., Maharjan, S., Choi, H., ... & Choi, D. Y. (2019). Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. The Journal of Nutritional Biochemistry, 69, 73-86.
Sureda, A., Daglia, M., Argüelles Castilla, S., et al. (2020). Oral microbiota and Alzheimer's disease: Do all roads lead to Rome? Pharmacol Res, 151, 104582.
Svensson, E., Horváth-Puhó, E., Thomsen, R.W., Djurhuus, J.C., Pedersen, L., Borghammer, P., et al. (2015). Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol, 78(4), 522–529.
Ton, A. M. M., Campagnaro, B. P., Alves, G. A., Aires, R., Côco, L. Z., Arpini, C. M., ... & Vasquez, E. C. (2020). Oxidative stress and dementia in Alzheimer’s patients: effects of synbiotic supplementation. Oxidative medicine and cellular longevity, 2020(1), 2638703.
Toral-Rios, D., Pichardo-Rojas, P. S., Alonso-Vanegas, M., & Campos-Pena, V. (2020). GSK3β and tau protein in Alzheimer’s disease and epilepsy. Front Cell Neurosci 14: 1–9.
Vasiliu, O. (2023). The current state of research for psychobiotics use in the management of psychiatric disorders–A systematic literature review. Frontiers in Psychiatry, 14, 1074736.
Vaz, M., & Silvestre, S. (2020). Alzheimer's disease: Recent treatment strategies. European journal of pharmacology, 887, 173554.
Vicentini, F.A., Keenan, C.M., Wallace, L.E., Woods, C., Cavin, J.B., Flockton, A.R., et al. (2021). Gut microbiota shapes intestinal physiology and regulates enteric neurons and glia. Microbiome, 9, 1–24.
Vodička, M., Ergang, P., Hrnčíř, T., Mikulecká, A., Kvapilová, P., Vagnerová, K., et al. (2018). Microbiota affects the expression of genes involved in HPA axis regulation and local metabolism of glucocorticoids in chronic psychosocial stress. Brain, Behavior, and Immunity, 73, 615–624.
Voet, S., Srinivasan, S., Lamkanfi, M., & van Loo, G. (2019). Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med, 11(6), e10248.
Wang, Q., Yang, Q., & Liu, X. (2023). The microbiota-gut-brain axis and neurodevelopmental disorders. Protein & Cell, 14(10), 762–775.
Wilson, D.M. III, Cookson, M.R., Van Den Bosch, L., Zetterberg, H., Holtzman, D.M., & Dewachter, I. (2023). Hallmarks of neurodegenerative diseases. Cell, 186(4), 693–714.
World Health Organization. (2025). https://www.who.int/news-room/fact-sheets/detail/dementia?ysclid=mqjj47b7x6427938840
Xiang, S., Ji, J.L., Li, S., Cao, X.P., Xu, W., Tan, L., et al. (2022). Efficacy and safety of probiotics in the treatment of Alzheimer's disease, mild cognitive impairment, and Parkinson's disease: A systematic review and meta-analysis. Front Aging Neurosci, 14, 730036.
Yan, X., Shi, L., Zhu, X., Zhao, Y., Luo, J., Li, Q., ... & Zhao, J. (2025). From microbial homeostasis to systemic pathogenesis: a narrative review on gut flora's role in neuropsychiatric, metabolic, and cancer disorders. Journal of Inflammation Research, 8851–8873.
You, M., Chen, N., Yang, Y., Cheng, L., He, H., Cai, Y., et al. (2024). Gut microbiota-brain axis in neurological disorders. MedComm, 5(8), e656.